Immunogenicity and safety of a CRM-conjugated meningococcal ACWY vaccine administered concomitantly with routine vaccines starting at 2 months of age. - Wikidata - wikimedia - TriplyDB

Immunogenicity and safety of a CRM-conjugated meningococcal ACWY vaccine administered concomitantly with routine vaccines starting at 2 months of age.

Immunogenicity and safety of a CRM-conjugated meningococcal ACWY vaccine administered concomitantly with routine vaccines starting at 2 months of age.

http://www.wikidata.org/entity/Q34290891

about

History of Meningococcal Outbreaks in the United States: Implications for Vaccination and Disease Prevention.An international consensus approach to the management of atypical hemolytic uremic syndrome in children.Immunogenicity and safety of concomitant administration of a combined hepatitis A/B vaccine and a quadrivalent meningococcal conjugate vaccine in healthy adults.Safety and immunogenicity of meningococcal ACWY CRM197-conjugate vaccine in children, adolescents and adults in Russia.Use of MenACWY-CRM vaccine in children aged 2 through 23 months at increased risk for meningococcal disease: recommendations of the Advisory Committee on Immunization Practices, 2013.

P2860

Q30249427-F4AA7B9C-8F88-4932-9BE5-CB8CD0D7DE2C Q33421861-3861A869-1853-4CC7-8EF0-F8E7E6FAF9C3 Q38867474-983B96FE-64CC-4FF7-8076-7AAC4C5CDF7B Q41648169-820C711C-24CC-4E77-AD3F-D1CDDA05B582 Q51716182-26EC224E-B894-401B-88BD-563C6A85FE57

P2860

Immunogenicity and safety of a CRM-conjugated meningococcal ACWY vaccine administered concomitantly with routine vaccines starting at 2 months of age.

http://www.wikidata.org/entity/Q34290891

description

2013 nî lūn-bûn

@nan

2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Immunogenicity and safety of a ...... s starting at 2 months of age.

@ast

Immunogenicity and safety of a ...... s starting at 2 months of age.

@en

Immunogenicity and safety of a ...... s starting at 2 months of age.

@nl

type

label

Immunogenicity and safety of a ...... s starting at 2 months of age.

@ast

Immunogenicity and safety of a ...... s starting at 2 months of age.

@en

Immunogenicity and safety of a ...... s starting at 2 months of age.

@nl

prefLabel

Immunogenicity and safety of a ...... s starting at 2 months of age.

@ast

Immunogenicity and safety of a ...... s starting at 2 months of age.

@en

Immunogenicity and safety of a ...... s starting at 2 months of age.

@nl

P1433

Q34290891-0124B900-7239-49B3-B402-AAF876B9E6CE

P1476

Q34290891-02E00E02-0A25-4B91-BAB7-BE3A1BF7E01E

P2093

Q34290891-0EF17B93-A0C6-45F4-8DAD-F6676481DF7D

Q34290891-3AE35F7B-4D00-4309-8455-13CB86181151

Q34290891-4D22DD4F-6249-4C2A-A730-820962DFF8D7

Q34290891-56DB1A02-CBB3-4C74-A534-F8410F0DCB66

Q34290891-74740BB6-DDBA-4AA3-BE06-58E0819AE237

Q34290891-7BC82B28-112A-4960-B552-2528E06A2302

Q34290891-8073AEE1-51BC-4CFE-AEA7-FDA19C46C280

Q34290891-F7B99667-D3C1-42AD-AA89-893FB8BB44D5

P2860

Q34290891-044B7A94-EC5C-43F2-8347-1099E63BAE34

Q34290891-04C52C88-3DC4-46F2-8500-BC93E589F5AE

Q34290891-08852B2E-EAF3-43DF-9D97-9C7DB1118F82

Q34290891-1BE0A798-2E0D-4CB5-A971-453470B8D316

Q34290891-1E3A802D-4F02-4BB2-A249-FCEE71D9CA09

Q34290891-22122EBF-3B8A-4925-8277-36A836FC0B16

Q34290891-30292120-4F17-43BA-88F2-35CA06EC0749

Q34290891-40526DF2-B6A4-4A04-94E9-85EA90205D0E

Q34290891-418E2E44-8044-42A5-B243-082C9E87D1BB

Q34290891-450C18F9-8287-4449-8559-137AB77DB83A

P304

Q34290891-43EC85D9-E6B0-44BE-A847-97054B566813

P31

Q34290891-393CD672-2586-4B36-AA89-5D31FFE4EF43

P356

Q34290891-B8D3BA4F-0C56-45FC-9FC9-A94445348711

P433

Q34290891-DB138DFE-840B-42C5-96B6-3DF5670CE598

P478

Q34290891-DA6AB9E3-89AF-4096-A1F9-61F8434507B1

P577

Q34290891-FF68DAF5-9F29-4D95-87E5-C9580F93B9A7

P698

Q34290891-03F123FE-B688-4CA7-A484-3CE8359A40B4

P932

Q34290891-99363FF9-F7CB-46FD-B98C-C74B65CF5633

P356

P1433

Human Vaccines & Immunotherapeutics

P1476

Immunogenicity and safety of a ...... s starting at 2 months of age.

@en

P2093

Aftab Naz

http://www.w3.org/2001/XMLSchema#string

Julie Shepard

http://www.w3.org/2001/XMLSchema#string

Lisa Bedell

http://www.w3.org/2001/XMLSchema#string

Matthew Hohenboken

http://www.w3.org/2001/XMLSchema#string

Michael D Nissen

http://www.w3.org/2001/XMLSchema#string

Peter M Dull

http://www.w3.org/2001/XMLSchema#string

Tatjana Odrljin

http://www.w3.org/2001/XMLSchema#string

Terry M Nolan

http://www.w3.org/2001/XMLSchema#string

P2860

Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction

Haemophilus influenzae type b conjugate vaccines: a review of efficacy data.

Randomized trial on the safety, tolerability, and immunogenicity of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, administered concomitantly with a combined tetanus, reduced diphtheria, and acellular pertussis va

Meningococcal disease.

Epidemiology of meningococcal disease in England and Wales 1993/94 to 2003/04: contribution and experiences of the Meningococcal Reference Unit.

Epidemic meningitis, meningococcaemia, and Neisseria meningitidis.

Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo®) or Menactra® among healthy adolescents

Critical appraisal of a quadrivalent CRM(197) conjugate vaccine against meningococcal serogroups A, C W-135 and Y (Menveo) in the context of treatment and prevention of invasive disease

A surveillance network for meningococcal disease in Europe.

Investigation of different group A immunoassays following one dose of meningococcal group A conjugate vaccine or A/C polysaccharide vaccine in adults.

P304

280-289

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4161/HV.27051

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2013-11-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24220326

http://www.w3.org/2001/XMLSchema#string

P932

4185919

http://www.w3.org/2001/XMLSchema#string